3 Q4 takeaways: COVID-19 testing strong (for now), electives hit, and M&A

As Yogi Berra famously said: "It's déjà vu all over again." With the fourth-quarter earnings season in full swing, medical device and diagnostics companies are feeling lingering effects, both positive and negative, from the COVID-19 pandemic.

What's clear is: the virus is a moving target and predictions are precarious.

While MedTech Dive continues its coverage of companies' fourth quarter and full-year financial disclosures, here are the trends that have emerged over the past few weeks and the market dynamics that might be expected from the industry for the rest of the year.